Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;11(3):273–288. doi: 10.1111/j.1527-3458.2005.tb00047.x

Pharmacological Properties, Central Nervous System Effects, and Potential Therapeutic Applications of Atipamezole, a Selective α2‐Adrenoceptor Antagonist

Antti Pertovaara 1,✉, Antti Haapalinna 2, Jouni Sirviö 2, Raimo Virtanen 2
PMCID: PMC6741735  PMID: 16389294

ABSTRACT

Atipamezole is an α2‐adrenoceptor antagonist with an imidazole structure. Receptor binding studies indicate that its affinity for α2‐adrenoceptors and its α2/α1 selectivity ratio are considerably higher than those of yohimbine, the prototype α2‐adrenoceptor antagonist. Atipamezole is not selective for subtypes of α2‐adrenoceptors. Unlike many other α2‐adrenoceptor antagonists, it has negligible affinity for 5‐HT1A and I2 bindings sites. Atipamezole is rapidly absorbed and distributed from the periphery to the central nervous system. In humans, atipamezole at doses up to 30 mg/subject produced no cardiovascular or subjective side effects, while at a high dose (100 mg/subject) it produced subjective symptoms, such as motor restlessness, and an increase in blood pressure. Atipamezole rapidly reverses sedation/anesthesia induced by α2‐adrenoceptor agonists. Due to this property, atipamezole is commonly used by veterinarians to awaken animals from sedation/anesthesia induced by α2‐adrenoceptor agonists alone or in combination with various anesthetics. Atipamezole increased sexual activity in rats and monkeys. In animals with sustained nociception, atipamezole increased pain‐related responses by blocking the noradrenergic feedback inhibition of pain. In tests assessing cognitive functions, atipamezole at low doses has beneficial effects on alertness, selective attention, planning, learning, and recall in experimental animals, but not necessarily on short‐term working memory. At higher doses atipamezole impaired performance in tests of cognitive functions, probably due to noradrenergic overactivity. Recent experimental animal studies suggest that atipamezole might have beneficial effects in the recovery from brain damage and might potentiate the anti‐Parkinsonian effects of dopaminergic drugs. In phase I studies atipamezole has been well tolerated by human subjects.

Keywords: α2‐Adrenoceptor antagonist, Anesthesia, Atipamezole, Cognition, Epilepsy, Ischemic brain damage, MPV‐1248, Memory, Pain, Parkinson's disease, Sexual behavior

Full Text

The Full Text of this article is available as a PDF (131.6 KB).

References

  • 1. Barbelivien A, Jolkkonen J, Rutkauskaite E, Sirviö J, Sivenius J. Differentially altered cerebral metabolism in ischemic rats by α2‐adrenoceptor blockade and its relations to improved limb‐placing reactions. Neuropharmacology 2002;42:117–126. [DOI] [PubMed] [Google Scholar]
  • 2. Berridge CW, Arnsten AFT, Foote SL. Noradrenergic modulation of cognitive function — clinical implications of anatomical, electrophysiological and behavioural studies in animal models. Psychol Med 1993;23:557–564. [DOI] [PubMed] [Google Scholar]
  • 3. Bidtnes V, Bals M, Viitamaa T, Ågmo A The adrenergic α2‐antagonist atipamezole enhances sexual incentive motivation in the male rat whereas yohimbine is ineffective. Soc Neurosci Abstr 2001;27:958.11. [Google Scholar]
  • 4. Carlson S, Tanila H, Rämä P, Mecke E, Pertovaara A. Effects of medetomidine, an alpha‐2 adrenoceptor agonist, and atipamezole, an alpha‐2 adrenoceptor antagonist, on spatial memory performance in adult and aged rats. Behav Neural Biol 1992;58:113–119. [DOI] [PubMed] [Google Scholar]
  • 5. Clarke RW, Harris J. RX 821002 as a tool for physiological investigation of α2‐adrenoceptors. CNS Drug Rev 2002;8:177–192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Durcan MJ, Lister RG, Linnoila M. Behavioral effects of α2 adrenoceptor antagonists and their interactions with ethanol in tests of locomotion, exploration and anxiety in mice. Psychopharmacology 1989;97:189–193. [DOI] [PubMed] [Google Scholar]
  • 7. Ewing KK, Mohammed HO, Scarlett JM, Short CE. Reduction of isoflurane anesthetic requirement by medetomidine and its restoration by atipamezole in dogs. Am J Vet Res 1993;54:294–299. [PubMed] [Google Scholar]
  • 8. Grauer E, Kapon Y. Wistar‐Kyoto rats in the Morris water maze: Impaired working memory and hyper‐reactivity to stress. Behav Brain Res 1993;59:147–151. [DOI] [PubMed] [Google Scholar]
  • 9. Green GM, Lyons L, Dickenson AH. Alpha2‐adrenoceptor antagonists enhance responses of dorsal horn neurones to formalin induced inflammation. Eur J Pharmacol 1998;347:201–204. [DOI] [PubMed] [Google Scholar]
  • 10. Gulia KK, Kumar VM, Mallick HN. Role of the lateral septal noradrenergic system in the elaboration of male sexual behavior in rats. Pharmacol Biochem Behav 2002;72:817–823. [DOI] [PubMed] [Google Scholar]
  • 11. Haapalinna A, Viitamaa T, MacDonald E et al. Evaluation of the effects of a specific alpha 2‐adrenoceptor antagonist, atipamezole, on alpha 1‐ and alpha 2‐adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine. Naunyn Schmiedeberg's Arch Pharmacol 1997;356:570–582. [DOI] [PubMed] [Google Scholar]
  • 12. Haapalinna A, Sirviö J, Lammintausta R. Facilitation of cognitive functions by a specific α2‐adrenoceptor antagonist, atipamezole. Eur J Pharmacol 1998;347:29–40. [DOI] [PubMed] [Google Scholar]
  • 13. Haapalinna A, MacDonald E, Viitamaa T, Salonen JS, Sirviö J, Virtanen R. Comparison of the effects of acute and subchronic administration of atipamezole on reaction to novelty and active avoidance learning in rats. Naunyn Schmiedeberg's Arch Pharmacol 1999;359:194–203. [DOI] [PubMed] [Google Scholar]
  • 14. Haapalinna A, Sirviö J, MacDonald E, Virtanen R, Heinonen E. The effects of a specific α2‐adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats. Eur J Pharmacol 2000;387:141–150. [DOI] [PubMed] [Google Scholar]
  • 15. Haapalinna A, Leino T, Heinonen E. The α2‐adrenoceptor antagonist atipamezole potentiates anti‐Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedeberg's Arch Pharmacol 2003;368:342–351. [DOI] [PubMed] [Google Scholar]
  • 16. Halonen T, Kotti T, Tuunanen J, et al. Alpha2‐adrenoceptor agonist, dexmedetomidine, protects against kainic acid‐induced convulsions and neuronal damage. Brain Res 1995;693:217–224. [DOI] [PubMed] [Google Scholar]
  • 17. Huupponen R, Karhuvaara S, Anttila M, Vuorilehto L, Scheinin M. Buccal delivery of an α2‐adrenergic receptor antagonist, atipamezole, in humans. Clin Pharmacol Ther 1995;58:506–511. [DOI] [PubMed] [Google Scholar]
  • 18. Jäkälä P, Sirviö J, Riekkinen P Jr, Haapalinna A, Riekkinen P. Effects of atipamezole, an α2‐adrenoceptor antagonist, on the performance of rats in a five‐choice serial reaction time task. Pharmacol Biochem Behav 1992;42:903–907. [DOI] [PubMed] [Google Scholar]
  • 19. Jalanka H. The use of medetomidine, medetomidine‐ketamine combinations and atipamezole at Helsinki Zoo — a review of 240 cases. Acta Vet Scand Suppl 1989;85:193–197. [PubMed] [Google Scholar]
  • 20. Jolkkonen J, Puurunen K, Rantakomi S, Härkönen A, Haapalinna A, Sivenius J. Behavioral effects of the α2‐adrenoceptor antagonist, atipamezole, after focal cerebral ischemia in rats. Eur J Pharmacol 2000;400:211–219. [DOI] [PubMed] [Google Scholar]
  • 21. Karhuvaara S, Kallio A, Scheinin M, Anttila M, Salonen JS, Scheinin H. Pharmacological effects and pharmacokinetics of atipamezole, a novel α2‐adrenoceptor antagonist — a randomized, double‐blind cross‐over study in healthy male volunteers. Br J Clin Pharmacol 1990;30:97–106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Kaukinen S, Pyykkö K. The potentiation of halothane anaesthesia by clonidine. Acta Anaesthesiol Scand 1979;23:107–111. [DOI] [PubMed] [Google Scholar]
  • 23. Kauppila T, Tanila H, Carlson S, Taira T. Effects of atipamezole, a novel alpha 2‐adrenoceptor antagonist, in open‐field, plus‐maze, two compartment exploratory, and forced swimming tests in the rat. Eur J Pharmacol 1991;205:177–182. [DOI] [PubMed] [Google Scholar]
  • 24. Kauppila T, Jyväsjärvi E, Pertovaara A. Effects of atipamezole, an α2‐adrenoceptor antagonist, on the anesthesia induced by barbiturates and medetomidine. Anesth Analg 1992;75:416–420. [DOI] [PubMed] [Google Scholar]
  • 25. Kauppila T, Jyväsjärvi E, Hämäläinen MM, Pertovaara A. The effect of selective α2‐adrenoceptor antagonist on pain behavior of the rat varies depending on experimental parameters. Pharmacol Biochem Behav 1998;59:477–485. [DOI] [PubMed] [Google Scholar]
  • 26. Laitinen KS, Tuomisto L, MacDonald E. Effects of a selective α2‐adrenoceptor antagonist, atipamezole, on hypothalamic histamine and noradrenaline release in vivo. Eur J Pharmacol 1995;285:255–260. [DOI] [PubMed] [Google Scholar]
  • 27. Linnankoski I, Grönroos M, Carlson S, Pertovaara A. Increased sexual behavior in male Macaca arctoides monkeys produced by atipamezole, a selective α2‐adrenoceptor antagonist. Pharmacol Biochem Behav 1992;42:197–200. [DOI] [PubMed] [Google Scholar]
  • 28. MacDonald E, Kobilka BK, Scheinin M. Gene targeting — homing in on α2‐adrenoceptor‐subtype function. Trends Pharmacol Sci 1997;18:211–219. [DOI] [PubMed] [Google Scholar]
  • 29. Mansikka H, Pertovaara A. Influence of selective α2‐adrenergic agents on mustard oil‐induced hyperalgesia in rats. Eur J Pharmacol 1995;281:43–48. [DOI] [PubMed] [Google Scholar]
  • 30. Mansikka H, Idänpään‐Heikkilä JJ, Pertovaara A. Different roles of α2‐adrenoceptors of the medulla versus the spinal cord in modulation of mustard oil‐induced hyperalgesia in rats. Eur J Pharmacol 1996;297:19–26. [DOI] [PubMed] [Google Scholar]
  • 31. Mansikka H, Lähdesmäki J, Scheinin M, Pertovaara A. α2A‐Adrenoceptors contribute to feedback inhibition of capsaicin‐induced hyperalgesia. Anesthesiology 2004;101:185–190. [DOI] [PubMed] [Google Scholar]
  • 32. Marien, MR , Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: A theory. Brain Res Rev 2004;45:38–78. [DOI] [PubMed] [Google Scholar]
  • 33. Mervaala E, Alhainen K, Helkala EL, et al. Electrophysiological and neuropsychological effects of a central α2‐adrenoceptor antagonist in healthy volunteers. Behav Brain Res 1993;55:85–91. [DOI] [PubMed] [Google Scholar]
  • 34. Niittykoski M, Hakkarainen V, Puumala T, et al. Systemic administration of atipamezole, an α2‐antagonist, can reduce scopolamine‐induced hyperactivity in rats. Behav Pharmacol 1997;8:465–470. [PubMed] [Google Scholar]
  • 35. Olave MJ, Maxwell DJ. Neurokinin‐1 projection cells in the rat dorsal horn receive synaptic contacts from axons that possess α2C‐adrenergic receptors. J Neurosci 2003;23:6837–6846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Olave MJ, Maxwell DJ. Axon terminals possessing α2C‐adrenergic receptors densely innervate neurons in the rat lateral spinal nucleus which respond to noxious stimulation. Neuroscience 2004;126:391–403. [DOI] [PubMed] [Google Scholar]
  • 37. Penttilä J, Kaila T, Helminen A, et al. Effects of atipamezole, a selective alpha‐adrenoceptor antagonist, on cardiac parasympathetic regulation in human subjects. Auton Autacoid Pharmacol 2004;24:69–75. [DOI] [PubMed] [Google Scholar]
  • 38. Pertovaara A. Antinociception induced by α2‐adrenoceptor agonists, with special emphasis on medetomidine studies. Prog Neurobiol 1993;40:691–709. [DOI] [PubMed] [Google Scholar]
  • 39. Pertovaara A. Antinociceptive properties of fadolmidine (MPV‐2426), a novel α2‐adrenoceptor agonist. CNS Drug Rev 2004;10:117–126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Pertovaara A, Bravo R, Herdegen T. Induction and suppression of immediate‐early genes by a selective alpha‐2‐adrenoceptor agonist and antagonist following peripheral stimulation. Neuroscience 1993;54:117–126. [DOI] [PubMed] [Google Scholar]
  • 41. Pertovaara A, Hämäläinen MM, Mecke E, Carlson S, Pertovaara A. Dissociation of the α2‐adrenergic antinociception from sedation following microinjection of medetomidine into the locus coeruleus in rats. Pain 1994;57:207–215. [DOI] [PubMed] [Google Scholar]
  • 42. Pertovaara A, Linnankoski I, Artchakov D, Rämä P, Carlson S. A potential aphrodisiac for female macaques. Pharmacol Biochem Behav 2004;79:137–141. [DOI] [PubMed] [Google Scholar]
  • 43. Pitkänen A, Narkilahti S, Bezvenyuk Z, Haapalinna A, Nissinen J. Atipamezole, an α2‐adrenoceptor antagonist, has disease modifying effects on epileptogenesis in rats. Epilepsy Res 2004;61:119–140. [DOI] [PubMed] [Google Scholar]
  • 44. Puurunen K, Sirviö J, Koistinaho J, et al. Studies on the influence of enriched‐environment housing combined with systemic administration of an α2‐adrenergic antagonists on spatial learning after global ischemia in rats. Stroke 1997;28:623–631. [DOI] [PubMed] [Google Scholar]
  • 45. Puurunen K, Jolkkonen J, Sirviö J, Haapalinna A, Sivenius J. An α2‐adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats. Neuropharmacology 2001;40:597–606. [DOI] [PubMed] [Google Scholar]
  • 46. Rämä P, Linnankoski I, Tanila H, Pertovaara A, Carlson S. Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacol Biochem Behav 1996;55:415–422. [DOI] [PubMed] [Google Scholar]
  • 47. Rämä P, Linnankoski I, Carlson S. The effects of α2 agonist, medetomidine and its antagonist, atipamezole on reaction and movement times in a visual choice reaction time task in monkeys. Brain Res Bull 1997;44:171–175. [DOI] [PubMed] [Google Scholar]
  • 48. Renouard A, Widdowson S, Millan MJ. Multiple α2 adrenergic receptor subtypes. I. Comparison of [3H]RX821002‐labeled rat R alpha‐2A adrenergic receptors in cerebral cortex to human H alpha‐2A adrenergic receptor and other populations of alpha‐2 adrenergic subtypes. J Pharmacol Exp Ther 1994;270:946–957. [PubMed] [Google Scholar]
  • 49. Riekkinen P Jr., Sirviö J, Jäkälä P, Lammintausta R, Riekkinen P. Effect of α2 antagonists and an agonist on EEG slowing induced by scopolamine and lesion of the nucleus basalis. Neuropharmacology 1990;29:993–999. [DOI] [PubMed] [Google Scholar]
  • 50. Riekkinen PJ, Sirviö J, Jäkälä P, Lammintausta R, Riekkinen P. Interaction between the alpha‐2 noradrenergic and muscarinic systems in the regulation of neocortical high voltage spindles. Brain Res Bull 1990;25:147–149. [DOI] [PubMed] [Google Scholar]
  • 51. Riekkinen P J, Riekkinen M, Jäkälä P, Lammintausta R, Riekkinen P. Combination of atipamezole and tetra‐hydroaminoacridine/pilocarpine treatment suppresses high voltage spindle activity in aged rats. Brain Res Bull 1991;27:237–239. [DOI] [PubMed] [Google Scholar]
  • 52. Riekkinen PJ, Sirviö J, Jäkälä P, Riekkinen M, Lammintausta R, Riekkinen P. Effects of alpha‐2 noradrenergic drugs and pilocarpine on the high voltage spindle activity of young and aged control and DSP‐4‐lesioned rats. Physiol Behav 1991;50:955–959. [DOI] [PubMed] [Google Scholar]
  • 53. Riekkinen PJ, Sirviö J, Valjakka A, Riekkinen M, Lammintausta R, Riekkinen P. Effects of atipamezole and tetrahydroaminoacridine on nucleus basalis lesion‐induced EEG changes. Brain Res Bull 1991;27:231–235. [DOI] [PubMed] [Google Scholar]
  • 54. Savontaus S, Raasmaja A, Rouru J, et al. Anti‐obesity effect of MPV‐1743 A III, a novel imidazoline derivative, in genetic obesity. Eur J Pharmacol 1997;328:207–215. [DOI] [PubMed] [Google Scholar]
  • 55. Scheinin H, MacDonald E, Scheinin M. Behavioural and neurochemical effects of atipamezole, a novel α2‐adrenoceptor antagonist. Eur J Pharmacol 1988;151:35–42. [DOI] [PubMed] [Google Scholar]
  • 56. Scheinin M, Lomasney JW, Hayden‐Hixson DM, et al. Distribution of α2‐adrenergic receptor subtype gene expression in rat brain. Mol Brain Res 1994;21:133–149. [DOI] [PubMed] [Google Scholar]
  • 57. Sirviö J, Lukkarinen K, Riekkinen P Jr, et al. The effects of atipamezole, and alpha‐2 antagonist, on the performance of young and aged rats in the delayed nonmatching to position task. Pharmacol Biochem Behav 1991;39:1015–1019. [DOI] [PubMed] [Google Scholar]
  • 58. Sirviö J, Harju M, Riekkinen P Jr., Haapalinna A, Riekkinen PJ. Comparative effects of alpha‐2 receptor agents and THA on the performance of adult and aged rats in the delayed non‐matching to position task. Psychopharmacology 1992;109:127–133. [DOI] [PubMed] [Google Scholar]
  • 59. Sirviö J, Riekkinen P Jr, MacDonald E, Airaksinen M, Lammintausta R, Riekkinen PJ. The effects of alpha‐2 adrenoceptor antagonist, atipamezole, on spatial learning in scopolamine‐treated and aged rats. J Neural Transm 1992;4:99–106. [DOI] [PubMed] [Google Scholar]
  • 60. Sirviö J, Jäkälä P, Mazurkiewicz M, Haapalinna A, Riekkinen P Jr, Riekkinen PJ. Dose‐ and parameter‐dependent effects of atipamezole, an α2‐antagonist, on the performance of rats in a five‐choice serial reaction time task. Pharmacol Biochem Behav 1993;45:123–129. [DOI] [PubMed] [Google Scholar]
  • 61. Stone LS, MacMillan LB, Kitto KF, Limbird LE, Wilcox GL. The alpha‐2A‐adrenergic receptor subtype mediates spinal analgesia evoked by alpha‐2‐agonists and is necessary for spinal adrenergic‐opioid synergy. J Neurosci 1997;17:7157–7165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Tanila H, Rämä P, Carlson S. The effects of prefrontal intracortical microinjections of an alpha‐2 agonist, alpha‐2 antagonist and lidocaine on the delayed alternation performance of aged rats. Brain Res Bull 1996;40:117–119. [DOI] [PubMed] [Google Scholar]
  • 63. Vainio O, Vähä‐Vahe T. Reversal of medetomidine sedation by atipamezole in dogs. J Vet Pharmacol Ther 1990;13:15–22. [DOI] [PubMed] [Google Scholar]
  • 64. Valjakka A, Lukkarinen K, Koivisto E, et al. Modulation of EEG rhythmicity and spike activity in the rat hippocampus by systemically administered tetrahydroamonoacridine, scopolamine and atipamezole. Brain Res Bull 1991;26:739–745. [DOI] [PubMed] [Google Scholar]
  • 65. Valjakka A, Lukkarinen K, Koivisto E, Lammintausta R, Airaksinen M, Riekkinen P. Evoked field responses, recurrent inhibition, long‐term potentiation and immobility‐related nonrhythmical EEG in the dentate gyrus of fimbria‐fornix‐lesioned and control rats. Brain Res Bull 1991;26:525–532. [DOI] [PubMed] [Google Scholar]
  • 66. Viitamaa T, Haapalinna A, Heinonen E. The effect of the α2‐adrenoceptor antagonist, atipamezole, on the sexual behavior of sexually low‐active male rats. Behav Pharmacol 1995;6:634–635. [Google Scholar]
  • 67. Virtanen R, Savola JM, Saano V. Highly selective and specific antagonism of central and peripheral α2‐adrenoceptors by atipamezole. Arch Int Pharmacodyn Ther 1989;297:190–204. [PubMed] [Google Scholar]
  • 68. Vogel WH, Harris N. Learning and memory of a water T‐maze by rats selectively bred for low or high plasma catecholamine stress response. Behav Neural Biol 1991;56:113–117. [DOI] [PubMed] [Google Scholar]
  • 69. Yavich L, Sirviö J, Haapalinna A, Ylinen A, Männistö PT. Atipamezole, an α2‐adrenoceptor antagonist, augments the effects of L‐DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol 2003;462:83–89. [DOI] [PubMed] [Google Scholar]
  • 70. Ylinen A, Pitkänen M, Pussinen R, et al. A selective antagonists of alpha‐2 adrenoceptors, facilitates the excitability of the dentate gyrus and improves the retention of the radial arm maze. Soc Neurosci Abstr 1996;22:680. [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES